{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:47:35Z","timestamp":1791460055607,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-025-06460-7","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T06:14:56Z","timestamp":1761372896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of RSV hospitalization on healthcare costs, caregivers\u2019 productivity loss, and quality of life in children\u2009\u2264\u20092\u00a0years old in five European countries"],"prefix":"10.1007","volume":"184","author":[{"given":"Joanne G.","family":"Wildenbeest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert W. J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Liese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cutrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Azzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Brouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martinon-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Herting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Epaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoonyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BRICE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Delestrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Faucon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Vittucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Streng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"10340","key":"6460_CR1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y et al (2022) Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 399(10340):2047\u20132064","journal-title":"Lancet"},{"issue":"2","key":"6460_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/irv.12443","volume":"11","author":"RM Reeves","year":"2017","unstructured":"Reeves RM et al (2017) Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007\u20132012. Influenza Other Respir Viruses 11(2):122\u2013129","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"6460_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES.2018.23.3.17-00163","volume":"23","author":"MT Jepsen","year":"2018","unstructured":"Jepsen MT et al (2018) Incidence and seasonality of respiratory syncytial virus hospitalisations in young children in Denmark, 2010 to 2015. Euro Surveill 23(3):17\u201300163","journal-title":"Euro Surveill"},{"issue":"10","key":"6460_CR4","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/INF.0000000000003640","volume":"41","author":"Y Oskarsson","year":"2022","unstructured":"Oskarsson Y et al (2022) Clinical and socioeconomic burden of Respiratory Syncytial Virus in Iceland. Pediatr Infect Dis J 41(10):800\u2013805","journal-title":"Pediatr Infect Dis J"},{"issue":"21","key":"6460_CR5","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1097\/MD.0000000000000831","volume":"94","author":"R Gil-Prieto","year":"2015","unstructured":"Gil-Prieto R et al (2015) Respiratory syncytial virus bronchiolitis in children up to 5 years of age in Spain: epidemiology and comorbidities: an observational study. Medicine (Baltimore) 94(21):e831","journal-title":"Medicine (Baltimore)"},{"issue":"45","key":"6460_CR6","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1016\/j.vaccine.2018.09.029","volume":"36","author":"R Kramer","year":"2018","unstructured":"Kramer R et al (2018) Cost and burden of RSV related hospitalisation from 2012 to 2017 in the first year of life in Lyon, France. Vaccine 36(45):6591\u20136593","journal-title":"Vaccine"},{"issue":"1","key":"6460_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1186\/s12879-021-06399-8","volume":"21","author":"C Demont","year":"2021","unstructured":"Demont C et al (2021) Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis 21(1):730","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6460_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s12879-023-08358-x","volume":"23","author":"F Martinon-Torres","year":"2023","unstructured":"Martinon-Torres F et al (2023) Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015\u20132018. BMC Infect Dis 23(1):385","journal-title":"BMC Infect Dis"},{"issue":"4","key":"6460_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","volume":"11","author":"JG Wildenbeest","year":"2023","unstructured":"Wildenbeest JG et al (2023) The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med 11(4):341\u2013353","journal-title":"Lancet Respir Med"},{"issue":"6","key":"6460_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB et al (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360(6):588\u2013598","journal-title":"N Engl J Med"},{"issue":"3","key":"6460_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/infdis\/jiac137","volume":"226","author":"K Hartmann","year":"2022","unstructured":"Hartmann K et al (2022) Clinical burden of respiratory syncytial virus in hospitalized children aged <\/=5 years (INSPIRE study). J Infect Dis 226(3):386\u2013395","journal-title":"J Infect Dis"},{"key":"6460_CR12","doi-asserted-by":"publisher","first-page":"594898","DOI":"10.3389\/fped.2020.594898","volume":"8","author":"E Bozzola","year":"2020","unstructured":"Bozzola E et al (2020) Respiratory syncytial virus bronchiolitis in infancy: the acute hospitalization cost. Front Pediatr 8:594898","journal-title":"Front Pediatr"},{"key":"6460_CR13","doi-asserted-by":"crossref","unstructured":"Wildenbeest JG et al (2025) Dynamics of RSV hospitalization rates in \u2264 2-year-old children between 2020-2023 in Europe. Eur J Pediatr 184(10):615","DOI":"10.1007\/s00431-025-06218-1"},{"key":"6460_CR14","unstructured":"European Medicines Agency. News. New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection. Sept 16, 2022. https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-protect-babies-infants-respiratory-syncytial-virus-rsv-infection. Accessed 9 Sept 2023"},{"key":"6460_CR15","unstructured":"US Food and Drug Administration. FDA news release. FDA Approves New Drug to Prevent RSV in Babies and Toddlers. July 17, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-prevent-rsv-babies-and-toddlers. Accessed 9 Sept 2023"},{"key":"6460_CR16","unstructured":"US Food and Drug Administration. FDA news release. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. August 21, 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants. Accessed 9 Sept 2023"},{"key":"6460_CR17","unstructured":"European Medicines Agency. News. First RSV vaccine to protect infants up to 6 months of age and older adults. July 21, 2023. https:\/\/www.ema.europa.eu\/en\/news\/first-rsv-vaccine-protect-infants-6-months-age-older-adults. Accessed 9 Sept 2023"},{"issue":"1","key":"6460_CR18","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","volume":"23","author":"NI Mazur","year":"2023","unstructured":"Mazur NI et al (2023) Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis 23(1):e2\u2013e21","journal-title":"Lancet Infect Dis"},{"key":"6460_CR19","unstructured":"US Food and Drug Administration. Highlights of prescribing information Clesrovimab-cfor. June 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761432s000lbl.pdf. Accessed 1 July 2025"},{"issue":"Suppl 7","key":"6460_CR20","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1093\/infdis\/jiz683","volume":"222","author":"S Zhang","year":"2020","unstructured":"Zhang S et al (2020) Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. J Infect Dis 222(Suppl 7):S680\u2013S687","journal-title":"J Infect Dis"},{"issue":"16","key":"6460_CR21","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","volume":"41","author":"Z Mao","year":"2023","unstructured":"Mao Z et al (2023) Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe. Vaccine 41(16):2707\u20132715","journal-title":"Vaccine"},{"issue":"10","key":"6460_CR22","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00431-005-1705-0","volume":"164","author":"B Ehlken","year":"2005","unstructured":"Ehlken B et al (2005) Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 164(10):607\u2013615","journal-title":"Eur J Pediatr"},{"issue":"12","key":"6460_CR23","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1002\/ppul.25621","volume":"56","author":"T Butel","year":"2021","unstructured":"Butel T et al (2021) Clinical course and cost assessment of infants with a first episode of acute bronchiolitis presenting to the emergency department: data from the GUERANDE clinical trial. Pediatr Pulmonol 56(12):3802\u20133812","journal-title":"Pediatr Pulmonol"},{"key":"6460_CR24","unstructured":"National Cost Collection for the NHS 2022-2023. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/. Accessed 15 Jan 2025"},{"key":"6460_CR25","first-page":"4521302","volume":"2017","author":"I Mitchell","year":"2017","unstructured":"Mitchell I, Defoy I, Grubb E (2017) Burden of Respiratory Syncytial Virus Hospitalizations in Canada. Can Respir J 2017:4521302","journal-title":"Can Respir J"},{"issue":"1","key":"6460_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12955-017-0654-4","volume":"15","author":"SA Schepers","year":"2017","unstructured":"Schepers SA et al (2017) Health related quality of life in Dutch infants, toddlers, and young children. Health Qual Life Outcomes 15(1):81","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"6460_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1023\/A:1008981603178","volume":"9","author":"M Fekkes","year":"2000","unstructured":"Fekkes M et al (2000) Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children. Qual Life Res 9(8):961\u2013972","journal-title":"Qual Life Res"},{"key":"6460_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/v16040507","author":"M Alchikh","year":"2024","unstructured":"Alchikh M et al (2024) Disease burden and inpatient management of children with acute respiratory viral infections during the pre-COVID era in Germany: a cost-of-illness study. Viruses. https:\/\/doi.org\/10.3390\/v16040507","journal-title":"Viruses"},{"issue":"1","key":"6460_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13052-024-01628-7","volume":"50","author":"M Dovizio","year":"2024","unstructured":"Dovizio M et al (2024) Clinical and economic burden of respiratory syncytial virus in children aged 0\u20135 years in Italy. Ital J Pediatr 50(1):57","journal-title":"Ital J Pediatr"},{"issue":"Suppl 2","key":"6460_CR30","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1093\/infdis\/jiac183","volume":"226","author":"EL Glaser","year":"2022","unstructured":"Glaser EL et al (2022) Impact of respiratory syncytial virus on child, caregiver, and family quality of life in the United States: systematic literature review and analysis. J Infect Dis 226(Suppl 2):S236\u2013S245","journal-title":"J Infect Dis"},{"issue":"29","key":"6460_CR31","doi-asserted-by":"crossref","first-page":"2100639","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100639","volume":"26","author":"J van Summeren","year":"2021","unstructured":"van Summeren J et al (2021) Low levels of respiratory syncytial virus activity in Europe during the 2020\/21 season: what can we expect in the coming summer and autumn\/winter? Euro Surveill 26(29):2100639","journal-title":"Euro Surveill"},{"issue":"5","key":"6460_CR32","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/irv.12998","volume":"16","author":"MN Billard","year":"2022","unstructured":"Billard MN et al (2022) International changes in respiratory syncytial virus (RSV) epidemiology during the COVID-19 pandemic: association with school closures. Influenza Other Respir Viruses 16(5):926\u2013936","journal-title":"Influenza Other Respir Viruses"},{"issue":"12","key":"6460_CR33","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/cid\/ciaa1475","volume":"72","author":"DK Yeoh","year":"2021","unstructured":"Yeoh DK et al (2021) Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis 72(12):2199\u20132202","journal-title":"Clin Infect Dis"},{"key":"6460_CR34","first-page":"100582","volume":"25","author":"M VinetaParamo","year":"2023","unstructured":"VinetaParamo M et al (2023) Respiratory syncytial virus epidemiology and clinical severity before and during the COVID-19 pandemic in British Columbia, Canada: a retrospective observational study. Lancet Reg Health Am 25:100582","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"6460_CR35","doi-asserted-by":"publisher","first-page":"e2023065623","DOI":"10.1542\/peds.2023-065623","volume":"154","author":"ML McMorrow","year":"2024","unstructured":"McMorrow ML et al (2024) Respiratory syncytial virus-associated hospitalizations in children<5 years: 2016-2022. Pediatrics 154(1):e2023065623","journal-title":"Pediatrics"},{"issue":"10","key":"6460_CR36","doi-asserted-by":"publisher","first-page":"e2336863","DOI":"10.1001\/jamanetworkopen.2023.36863","volume":"6","author":"M Bourdeau","year":"2023","unstructured":"Bourdeau M et al (2023) Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic. JAMA Netw Open 6(10):e2336863","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6460_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2352-4642(22)00371-6","volume":"7","author":"U Nygaard","year":"2023","unstructured":"Nygaard U et al (2023) Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study. Lancet Child Adolesc Health 7(3):171\u2013179","journal-title":"Lancet Child Adolesc Health"},{"key":"6460_CR38","doi-asserted-by":"publisher","first-page":"105530","DOI":"10.1016\/j.jcv.2023.105530","volume":"166","author":"A Kiefer","year":"2023","unstructured":"Kiefer A et al (2023) Comparative analysis of RSV-related hospitalisations in children and adults over a 7 year-period before, during and after the COVID-19 pandemic. J Clin Virol 166:105530","journal-title":"J Clin Virol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-025-06460-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-025-06460-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T07:35:37Z","timestamp":1762846537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-025-06460-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6460"],"URL":"https:\/\/doi.org\/10.1007\/s00431-025-06460-7","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from all study sites prior to the initiation of the research; Ethikkommission der Universit\u00e4t zu L\u00fcbeck (no. 20\u2013345) and Ethik-Kommission der Universit\u00e4t W\u00fcrzburg (no. 1\/20_z) in Germany, Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n de Santiago y Lugo (no. 2020\/452) and Comit\u00e9 de \u00c9tica de la Investigaci\u00f3n Hospital Universitario La Paz (no. 22\/2020) in Spain; Comitato Etico Regione Toscana\u2014Pediatricoc\/o Azienda Ospedaliero Universitaria Meyer (no. 247\/2020) and Comitato Etico Ospedale Pediatrico Bambino Ges\u00f9 IRCCS (no. 2275\/2020) in Italy; London\u2014Brighton & Sussex Research Ethics Committee (no. 21\/LO\/0578) in England; Comit\u00e9 de protection des personnes Sud Ouest et Outre Mer IV Cabanis Haut \u2013 Centre Cabanis Haut (no. 20.10.09.60811\/CPP2020-11-094b) in France. Written informed consent was obtained from the parents\/legally authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Yoonyoung Choi and Madelyn Ruggieri are employees at Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. FM-T has acted as principal investigator in randomized controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur, MSD, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK, with honoraria paid to his institution. FM-T reports a relationship with GSK Vaccines SRL that includes consulting or advisory. FM-T reports a relationship with Pfizer Inc that includes consulting or advisory. FM-T reports a relationship with Sanofi Pasteur Inc that includes consulting or advisory. FM-T reports a relationship with Janssen Pharmaceuticals Inc that includes consulting or advisory. FM-T reports a relationship with MSD that includes consulting or advisory. FM-T reports a relationship with Seqirus Pty Ltd that includes consulting or advisory. SBD has previously received honoraria from Sanofi for taking part in RSV advisory boards and has provided consultancy and\/or investigator roles in relation to product development for Janssen, AstraZeneca, Pfizer, Moderna, Valneva, MSD, iLiAD and Sanofi with fees paid to my institution. SBD is a member of the UK Department of Health and Social Care\u2019s (DHSC) Joint Committee on Vaccination and Immunisation (JCVI) RSV subcommittee and Medicines and Healthcare products Regulatory Agency\u2019s (MHRA) Paediatric Medicine Expert Advisory Group (PMEAG), but the reviews expressed herein do not necessarily represent those of DHSC, JCVI, MHRA or PMEAG. JGW has been an investigator for clinical trials sponsored by pharmaceutical companies including AstraZeneca, MSD, Pfizer, Sanofi, and Janssen and an investigator for clinical trials funded by IMI\/Horizon2020 and ZonMw. All funds have been paid to UMCU. JGW participated in advisory boards of Janssen and Sanofi and was a speaker at a Sanofi sponsored symposium with honoraria paid to UMCU. LB has regular interaction with pharmaceutical and other industrial partners. He has not received personal fees or other personal benefits. UMCU has received major funding (>\u2009\u20ac100,000 per industrial partner) for investigator initiated studies from AstraZeneca, Sanofi, Janssen, Pfizer, MSD and MeMed Diagnostics. UMCU has received major funding from the Bill and Melinda Gates Foundation. UMCU has received major funding as part of the public private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer and Sanofi. UMCU has received major funding by Julius Clinical for participating in clinical studies sponsored by AstraZeneca, Merck and Pfizer. UMCU received minor funding (\u20ac1000\u201325,000 per industrial partner) for consultation, DSMB membership or invited lectures by Ablynx, Bavaria Nordic, GSK, Novavax, Pfizer, Moderna, Astrazeneca, MSD, Sanofi, Janssen. LB is the founding chairman of the ReSViNET Foundation. EH has received speaking fees and travel support from Pfizer, MSD, Sanofi, Abbvie\/AstraZeneca and Chiesi. RE has previously received honoraria for lectures, expertise or educational events. RE has previously received honoraria from AstraZeneca and Sanofi for taking part in RSV advisory boards and also from AstraZeneca, GSK Pfizer, and Sanofi for lectures, expertise or educational events. RE has acted as principal investigator in randomized controlled trials of AstraZeneca, Sanofi, GSK, with honoraria paid to his institution. JB has previously received honoraria from MSD and ALK for taking part in advisory boards and from AstraZeneca, MSD, and Sanofi for lectures, expertise or educational events. JL has been an investigator for clinical trials sponsored by pharmaceutical companies including AstraZeneca, GSK, MSD, Pfizer and Sanofi and received consulting or lecture fees from Enanta, Engelhard Pharma, Gilead Sciences, MSD, Pfizer, Sanofi and Siemens Health Care. CA has received fees for meetings or consulting or advisory boards from Astra Zeneca, GSK, MSD, Moderna, Novavax, Pfizer, Sanofi.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"716"}}